Immediate Impact
2 from Science/Nature 82 standout
Citing Papers
CAR immune cells: design principles, resistance and the next generation
2023 StandoutNature
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
2023 Standout
Works of Joy Mangel being referenced
A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
2012
A pilot study of central venous catheter survival in cancer patients using low‐molecular‐weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study)
2007
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Joy Mangel | 445 | 290 | 312 | 47 | 933 | |
| U Hess | 378 | 336 | 300 | 45 | 932 | |
| Luca Laurenti | 236 | 265 | 385 | 40 | 1.1k | |
| James N. Butera | 531 | 619 | 159 | 55 | 1.1k | |
| Shayna Sarosiek | 165 | 175 | 341 | 101 | 1.1k | |
| A Bernadou | 261 | 191 | 173 | 49 | 752 | |
| Cynthia Rutherford | 202 | 263 | 207 | 34 | 1.1k | |
| Darko Antić | 236 | 166 | 189 | 90 | 780 | |
| Kathleen Jentsch‐Ullrich | 143 | 144 | 235 | 46 | 862 | |
| Martin Mohren | 192 | 189 | 167 | 38 | 927 | |
| Shmuel Gillis | 110 | 107 | 211 | 44 | 1.1k |
All Works
Login with ORCID to disown or claim papers
Loading papers...